FTREHIGH SIGNALFINANCIAL10-K

Fortrea experienced substantial deterioration in financial position with stockholders' equity declining significantly and operating cash flow falling meaningfully below prior year levels.

The company's financial foundation has weakened considerably, with equity declining by nearly 60% while total assets contracted by about a quarter. The substantial reduction in operating cash flow generation raises questions about operational efficiency and cash management during what appears to be a challenging period for the contract research organization.

Comparing 2026-02-26 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

Fortrea's financial profile deteriorated markedly during the period, with stockholders' equity falling substantially to $563.5M and operating cash flow declining meaningfully to $113.5M. While the company improved its cash position to $174.6M and reduced SG&A expenses by 18.6%, the overall picture suggests significant financial stress. The reduction in total assets by nearly a quarter alongside the equity decline indicates potential asset write-downs or other balance sheet restructuring activities that investors should monitor closely.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-58.6%
$1.4B→$563.5M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
-56.8%
$262.8M→$113.5M

Operating cash flow fell 56.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
+47.3%
$118.5M→$174.6M

Cash position surged 47.3% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
-24.1%
$3.6B→$2.7B

Total assets contracted 24.1% — asset sales, write-downs, or balance sheet optimization underway.

SG&A Expense
P&L
-18.6%
$560.7M→$456.4M

SG&A reduced 18.6% — improved cost efficiency or headcount reduction improving operating margins.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-03
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 56 Item 7A.
Our team of approximately 14,300 employees is able to conduct operations in approximately 100 countries.
Our solutions include our clinical research units ( CRUs ) and external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics ( PK ), modeling and simulation, and biometrics.
A global bedside data capture system has been implemented across all CRUs, enabling increased efficiency and quality, and providing real time access to data.
Our service offerings are supported by technological innovations, leveraging strategic relationships with leading technology vendors together with Fortrea s operational expertise to support more connected patient and site centric solutions, digital health and decentralized clinical trial capabilities.
We are making focused investments in artificial intelligence ( AI ), machine learning ( ML ), other advanced technologies, and workflow automation and orchestration to drive speed, agility, quality and enhanced patient safety in clinical research.
For instance, during the period from January 2020 to December 2024, we conducted more than 5,930 phase I through IV clinical trial projects involving approximately 1,000,000 subjects.
We also have a medical device and diagnostics offering, which has conducted more than 500 studies during that same period.
As a result, bringing a new biopharmaceutical product to market takes about a decade 1 and costs $2.23 billion on average.
Phase I-IV clinical development spend by the pharmaceutical and biotechnology industry is forecast to be ~$145 billion in 2026 3 .
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 54 Item 7A.
Our team of approximately 15,500 employees provides services in approximately 100 countries.
Our solutions include our clinical pharmacology units and external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics ( PK ), modeling and simulation, and biometrics.
Fortrea s clinical research units ( CRUs ) are located in Leeds, U.K.
A global bedside data capture system has been implemented across all CRUs.
Our service offerings are supported by technological innovations such as digital and decentralized clinical trial capabilities.
Over the previous five years, we have conducted more than 5,925 phase I through IV clinical trial projects involving more than 1,000,000 subjects.
We also have a medical device and diagnostics offering, which has conducted more than 500 studies in the previous five years.
As a result, bringing a new biopharmaceutical product or medical device to market can take up to 12 years 1 and costs $2.3 billion or more on average.
The clinical development market is a large, attractive and growing market.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →